A Promising Drug Target: TOLLIP (G54472)

Target Name: TOLLIP

NCBI ID: G54472

A Promising Drug Target: TOLLIP

Tollipin (Tgp) is a transmembrane protein that is expressed in various tissues and cell types in the human body. It is involved in many physiological processes, including cell signaling, migration, and invasion. Tollipin has also been implicated in several diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. As a result, targeting Tollipin has become an attractive research topic in the pharmaceutical industry.

Drug Targeting

Tollipin is a potential drug target because of its unique structure and biology. It is a monocysteine-containing protein that consists of a long transmembrane domain and a short cytoplasmic tail. The transmembrane domain contains a cryptic region that is involved in several protein-protein interactions, including the interaction with the protein p120GAP. This interaction suggests that Tollipin may play a role in intracellular signaling pathways.

Furthermore, Tollipin has been shown to have a unique expression pattern in various tissues and cancer types. For example, it has been shown to be highly expressed in various types of cancer, including breast, ovarian, and prostate cancer. This suggests that Tollipin may be a useful biomarker for cancer diagnosis and treatment.

Biomarker Potential

Tollipin has also been shown to be involved in several biomarker pathways that are relevant to cancer diagnosis and treatment. For example, Tollipin has been shown to be involved in the angiogenesis process, which is the process by which tumors grow and establish blood supply. Therefore, Tollipin may be a useful biomarker for cancer diagnosis and treatment by targeting angiogenesis.

In addition, Tollipin has been shown to be involved in the regulation of cellular signaling pathways, including the TGF-β pathway. This pathway is involved in cell signaling, including cell growth, differentiation, and inflammation. Therefore, Tollipin may be a useful biomarker for monitoring the effectiveness of anti-cancer drugs.

Disease-Related Potential

Tollipin has also been implicated in several diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. For example, Tollipin has been shown to be involved in the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. This suggests that Tollipin may be a useful target for neurodegenerative disease treatment.

In addition, Tollipin has also been implicated in the development and progression of autoimmune diseases, including rheumatoid arthritis and multiple sclerosis. This suggests that Tollipin may be a useful target for autoimmune disease treatment.

Conclusion

Tollipin is a unique protein that has been shown to be involved in several physiological processes and diseases. As a result, targeting Tollipin has become an attractive research topic in the pharmaceutical industry. The potential drug targets and biomarker potential of Tollipin make it an attractive target for future research.

Targeting Tollipin

Currently, there are several drugs that are being developed to target Tollipin. These drugs include small molecules, peptides, and antibodies. These drugs are being tested for their potential to treat a range of diseases, including cancer, neurodegenerative disorders, and autoimmune diseases.

One of the most promising drugs being developed to target Tollipin is a small molecule inhibitor of Tollipin, called TG-112052. This drug is being tested

Protein Name: Toll Interacting Protein

Functions: Component of the signaling pathway of IL-1 and Toll-like receptors (PubMed:10854325, PubMed:11751856). Inhibits cell activation by microbial products. Recruits IRAK1 to the IL-1 receptor complex (PubMed:10854325). Inhibits IRAK1 phosphorylation and kinase activity (PubMed:11751856). Connects the ubiquitin pathway to autophagy by functioning as a ubiquitin-ATG8 family adapter and thus mediating autophagic clearance of ubiquitin conjugates (PubMed:25042851). The TOLLIP-dependent selective autophagy pathway plays an important role in clearance of cytotoxic polyQ proteins aggregates (PubMed:25042851). In a complex with TOM1, recruits ubiquitin-conjugated proteins onto early endosomes (PubMed:15047686). Binds to phosphatidylinositol 3-phosphate (PtdIns(3)P) (PubMed:26320582)

More Common Targets